Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) FCF Margin (2016 - 2025)

Capricor Therapeutics has reported FCF Margin over the past 15 years, most recently at 58706.66% for Q1 2025.

  • Quarterly results put FCF Margin at 58706.66% for Q1 2025, down 5868789.0% from a year ago — trailing twelve months through Dec 2025 was 582424.69% (down 58227426.0% YoY), and the annual figure for FY2024 was 184.83%, down 7796.0%.
  • FCF Margin for Q1 2025 was 58706.66% at Capricor Therapeutics, down from 137.33% in the prior quarter.
  • Over the last five years, FCF Margin for CAPR hit a ceiling of 129.32% in Q1 2023 and a floor of 58706.66% in Q1 2025.
  • Median FCF Margin over the past 5 years was 351.61% (2024), compared with a mean of 5384.24%.
  • Biggest five-year swings in FCF Margin: surged 328386bps in 2023 and later tumbled -5868789bps in 2025.
  • Capricor Therapeutics' FCF Margin stood at 2370.08% in 2021, then soared by 67bps to 791.34% in 2022, then surged by 87bps to 100.53% in 2023, then tumbled by -37bps to 137.33% in 2024, then crashed by -42650bps to 58706.66% in 2025.
  • The last three reported values for FCF Margin were 58706.66% (Q1 2025), 137.33% (Q4 2024), and 515.18% (Q3 2024) per Business Quant data.